DTIL VS EVGN Stock Comparison
Performance
DTIL10/100
10/100
DTIL returned -79.21% in the last 12 months. Based on SPY's performance of -20.66%, its performance is below average giving it a score of 10 of 100.
EVGN10/100
10/100
EVGN returned -10.89% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Sentiment
DTIL68/100
68/100
DTIL had a bullish sentiment score of 68.05% across Twitter and StockTwits over the last 12 months. It had an average of 8.75 posts, 4.76 comments, and 13.29 likes per day.
EVGN
"Sentiment" not found for EVGN
Technicals
DTIL14/100
14/100
DTIL receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
EVGN64/100
64/100
EVGN receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.
Earnings
DTIL10/100
10/100
DTIL has missed earnings 5 times in the last 20 quarters.
EVGN17/100
17/100
EVGN has missed earnings 4 times in the last 20 quarters.
Profit
DTIL10/100
10/100
Out of the last 20 quarters, DTIL has had 1 profitable quarters and has increased their profits year over year on 1 of them.
EVGN10/100
10/100
Out of the last 20 quarters, EVGN has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
DTIL32/100
32/100
DTIL has had a lower than average amount of volatility over the last 12 months giving it a score of 32 of 100.
EVGN54/100
54/100
EVGN has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.
Analyst Price Targets
DTIL
"Analyst Price Targets" not found for DTIL
EVGN63/100
63/100
2 analysts offer 12-month price targets for EVGN. Together, they have an average target of 0, the most optimistic target put EVGN at 0 within 12-months and the most pessimistic has EVGN at 0.
All score calculations are broken down here to help you make more informed investing decisions
Precision BioSciences, Inc. Common Stock Summary
Nasdaq / DTIL
Healthcare
Biotechnology
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
EVOGENE LTD. Summary
Nasdaq / EVGN
Healthcare
Biotechnology
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare DTIL to other companies in the same or a similar industry.